Pfizer and Allergan merger to create uncertainty for agencies, execs say

The deal has also been criticized as a tax dodge as it will allow New York-based Pfizer to move its headquarters abroad.

by Kevin McCaffrey, Medical Marketing & Media

To continue reading this article you need to be registered with Campaign. Registration is free and only takes a minute. Register here or sign in below if you already have an account.

Sign in


  • Limited free articles a month
  • Free email bulletins

Register Now

Become a member

From $169 a year

  • Full access to
  • Exclusive event discounts
  • Plus lots more...

Choose a package

Need to activate  your membership?